The CheckMate 649 trial demonstrated that nivolumab plus chemotherapy significantly extended both OS and PFS compared with chemotherapy in patients with advanced GC, particularly among those with PD-L1 combined positive score (CPS)≥5 (10). This evidence concerns the gene CD274 and gastric cancer.